Bio News
Researchers at the University of Helsinki found that simultaneously blocking mitochondrial respiration and glutamine metabolism causes synthetic lethality in MYC-high breast cancer cells. The University of Helsinki team leveraged the dependence of MYC-high cells on mitochondrial complex I and glutamine breakdown to inhibit tumor growth in a mouse model by combining inhibitors of the two pathways. Based on the finding, the University of Helsinki has launched a project to develop a single drug that simultaneously inhibits both targets.
BIOBOOK TEAM
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
